Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Muscle, Smooth, Vascular | 6 | 2013 | 71 | 1.080 |
Why?
|
Myocytes, Smooth Muscle | 4 | 2013 | 74 | 0.800 |
Why?
|
Carotid Arteries | 6 | 2013 | 97 | 0.660 |
Why?
|
Blood Vessel Prosthesis | 4 | 2012 | 78 | 0.630 |
Why?
|
Tunica Intima | 5 | 2005 | 59 | 0.570 |
Why?
|
Endothelial Cells | 5 | 2012 | 179 | 0.550 |
Why?
|
Extracellular Matrix Proteins | 1 | 2013 | 40 | 0.460 |
Why?
|
RGS Proteins | 4 | 2007 | 18 | 0.460 |
Why?
|
Hyaluronic Acid | 1 | 2013 | 45 | 0.460 |
Why?
|
Carotid Stenosis | 1 | 2013 | 56 | 0.450 |
Why?
|
Tissue Scaffolds | 4 | 2012 | 386 | 0.400 |
Why?
|
Tissue Engineering | 3 | 2012 | 608 | 0.390 |
Why?
|
Stem Cells | 2 | 2010 | 292 | 0.370 |
Why?
|
Stents | 3 | 2009 | 171 | 0.330 |
Why?
|
Blood Vessels | 2 | 2008 | 47 | 0.330 |
Why?
|
Arteriosclerosis | 3 | 2004 | 116 | 0.320 |
Why?
|
Venous Thrombosis | 3 | 2019 | 48 | 0.310 |
Why?
|
Blood Vessel Prosthesis Implantation | 3 | 2012 | 68 | 0.290 |
Why?
|
Cells, Cultured | 6 | 2013 | 799 | 0.290 |
Why?
|
Iliac Artery | 2 | 2002 | 46 | 0.260 |
Why?
|
Gene Expression Profiling | 2 | 2005 | 320 | 0.260 |
Why?
|
Enzyme Inhibitors | 2 | 2004 | 162 | 0.250 |
Why?
|
Catheterization | 2 | 2019 | 58 | 0.250 |
Why?
|
Popliteal Vein | 2 | 2019 | 3 | 0.250 |
Why?
|
Femoral Vein | 2 | 2019 | 10 | 0.250 |
Why?
|
Animals | 12 | 2013 | 7297 | 0.250 |
Why?
|
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2004 | 2 | 0.240 |
Why?
|
Protein-Serine-Threonine Kinases | 1 | 2004 | 44 | 0.240 |
Why?
|
Renal Dialysis | 2 | 2019 | 259 | 0.230 |
Why?
|
Time Factors | 8 | 2013 | 1997 | 0.230 |
Why?
|
Hyperplasia | 3 | 2013 | 38 | 0.230 |
Why?
|
Cell Adhesion | 3 | 2013 | 103 | 0.220 |
Why?
|
Genes | 1 | 2002 | 15 | 0.220 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2002 | 155 | 0.220 |
Why?
|
Metalloendopeptidases | 1 | 2002 | 11 | 0.210 |
Why?
|
Hydroxamic Acids | 1 | 2002 | 17 | 0.210 |
Why?
|
Jugular Veins | 2 | 2012 | 26 | 0.200 |
Why?
|
Neovascularization, Physiologic | 1 | 2002 | 106 | 0.200 |
Why?
|
Arteriovenous Shunt, Surgical | 2 | 2012 | 45 | 0.200 |
Why?
|
Aorta | 3 | 2007 | 103 | 0.190 |
Why?
|
Vascular Surgical Procedures | 3 | 2013 | 91 | 0.180 |
Why?
|
Biomedical Research | 2 | 2013 | 153 | 0.180 |
Why?
|
Sheep | 5 | 2012 | 221 | 0.180 |
Why?
|
Collagen Type I | 2 | 2013 | 39 | 0.170 |
Why?
|
Patient Selection | 2 | 2019 | 257 | 0.170 |
Why?
|
Thrombolytic Therapy | 1 | 2019 | 59 | 0.170 |
Why?
|
Vascular Diseases | 2 | 2013 | 61 | 0.160 |
Why?
|
Prosthesis Design | 4 | 2012 | 87 | 0.160 |
Why?
|
Renal Artery Obstruction | 2 | 2009 | 38 | 0.160 |
Why?
|
Macaca fascicularis | 3 | 2004 | 389 | 0.150 |
Why?
|
Mice, Inbred C57BL | 2 | 2013 | 711 | 0.150 |
Why?
|
Pulsatile Flow | 3 | 2012 | 25 | 0.140 |
Why?
|
Bioreactors | 3 | 2012 | 59 | 0.140 |
Why?
|
Renal Artery | 2 | 2006 | 43 | 0.130 |
Why?
|
Collagen | 2 | 2008 | 217 | 0.130 |
Why?
|
Tyrosine | 2 | 2004 | 22 | 0.130 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 518 | 0.120 |
Why?
|
Stress, Mechanical | 2 | 2012 | 90 | 0.120 |
Why?
|
Cell Shape | 1 | 2013 | 26 | 0.120 |
Why?
|
Graft Occlusion, Vascular | 2 | 2012 | 21 | 0.120 |
Why?
|
Lipoproteins, HDL | 2 | 2007 | 247 | 0.110 |
Why?
|
Mice | 2 | 2013 | 2368 | 0.110 |
Why?
|
Health Priorities | 1 | 2013 | 14 | 0.110 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 23 | 0.110 |
Why?
|
Cardiovascular Agents | 1 | 2013 | 18 | 0.110 |
Why?
|
Rats | 3 | 2013 | 1604 | 0.110 |
Why?
|
Cell Culture Techniques | 2 | 2012 | 165 | 0.110 |
Why?
|
Recurrence | 1 | 2013 | 235 | 0.110 |
Why?
|
Male | 14 | 2019 | 17768 | 0.110 |
Why?
|
Materials Testing | 2 | 2012 | 83 | 0.110 |
Why?
|
Cell Movement | 1 | 2013 | 161 | 0.110 |
Why?
|
Coronary Artery Disease | 2 | 2007 | 358 | 0.110 |
Why?
|
Anticoagulants | 2 | 2019 | 120 | 0.110 |
Why?
|
Vascular Patency | 5 | 2012 | 66 | 0.110 |
Why?
|
Mice, Knockout | 1 | 2013 | 425 | 0.110 |
Why?
|
Societies, Medical | 1 | 2013 | 149 | 0.100 |
Why?
|
Blotting, Western | 2 | 2010 | 281 | 0.100 |
Why?
|
Female | 13 | 2019 | 18114 | 0.100 |
Why?
|
Hemodynamics | 1 | 2012 | 148 | 0.100 |
Why?
|
Stem Cell Transplantation | 2 | 2012 | 203 | 0.100 |
Why?
|
Signal Transduction | 2 | 2013 | 666 | 0.100 |
Why?
|
Vasoconstriction | 2 | 2011 | 40 | 0.100 |
Why?
|
RNA, Messenger | 4 | 2007 | 514 | 0.100 |
Why?
|
Rats, Sprague-Dawley | 1 | 2013 | 747 | 0.100 |
Why?
|
Cell Proliferation | 2 | 2010 | 573 | 0.090 |
Why?
|
Bioprosthesis | 1 | 2011 | 55 | 0.090 |
Why?
|
Intramolecular Oxidoreductases | 1 | 2010 | 5 | 0.090 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2010 | 28 | 0.090 |
Why?
|
Hypertension | 3 | 2007 | 899 | 0.090 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2010 | 37 | 0.090 |
Why?
|
Clinical Medicine | 1 | 2009 | 13 | 0.090 |
Why?
|
Angioplasty | 1 | 2009 | 31 | 0.090 |
Why?
|
Disease Models, Animal | 1 | 2013 | 980 | 0.090 |
Why?
|
Swine | 1 | 2010 | 201 | 0.090 |
Why?
|
Polyesters | 1 | 2008 | 72 | 0.080 |
Why?
|
Constriction, Pathologic | 2 | 2012 | 41 | 0.080 |
Why?
|
Regional Blood Flow | 2 | 2012 | 82 | 0.080 |
Why?
|
Peroxidase | 2 | 2004 | 33 | 0.080 |
Why?
|
Humans | 17 | 2019 | 29013 | 0.080 |
Why?
|
Arteries | 2 | 2004 | 60 | 0.080 |
Why?
|
Myosin Heavy Chains | 2 | 2011 | 86 | 0.080 |
Why?
|
Vena Cava Filters | 1 | 2007 | 14 | 0.080 |
Why?
|
Complement Activation | 1 | 2007 | 10 | 0.080 |
Why?
|
Prosthesis Implantation | 1 | 2007 | 35 | 0.080 |
Why?
|
Peptide Hydrolases | 1 | 2007 | 15 | 0.080 |
Why?
|
Down-Regulation | 2 | 2004 | 142 | 0.070 |
Why?
|
Device Removal | 1 | 2007 | 31 | 0.070 |
Why?
|
Vena Cava, Inferior | 1 | 2007 | 31 | 0.070 |
Why?
|
Iliac Vein | 1 | 2006 | 8 | 0.070 |
Why?
|
Pancreatitis, Acute Necrotizing | 1 | 2006 | 7 | 0.070 |
Why?
|
Angioplasty, Balloon | 1 | 2006 | 33 | 0.070 |
Why?
|
Proteomics | 1 | 2007 | 92 | 0.070 |
Why?
|
Balloon Occlusion | 1 | 2006 | 29 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2019 | 2106 | 0.070 |
Why?
|
Thrombectomy | 1 | 2006 | 58 | 0.070 |
Why?
|
Middle Aged | 9 | 2019 | 10805 | 0.070 |
Why?
|
Carboxypeptidases | 1 | 2005 | 20 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2004 | 641 | 0.070 |
Why?
|
Aged | 8 | 2019 | 9462 | 0.070 |
Why?
|
Viscera | 1 | 2004 | 17 | 0.060 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2005 | 75 | 0.060 |
Why?
|
Hypochlorous Acid | 1 | 2004 | 2 | 0.060 |
Why?
|
Reactive Nitrogen Species | 1 | 2004 | 5 | 0.060 |
Why?
|
Carotid Artery Diseases | 1 | 2005 | 109 | 0.060 |
Why?
|
Phenotype | 2 | 2005 | 629 | 0.060 |
Why?
|
Arterial Occlusive Diseases | 1 | 2004 | 30 | 0.060 |
Why?
|
Aorta, Thoracic | 1 | 2005 | 72 | 0.060 |
Why?
|
Intestine, Small | 1 | 2004 | 34 | 0.060 |
Why?
|
Aneurysm | 1 | 2004 | 21 | 0.060 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2004 | 60 | 0.060 |
Why?
|
rho-Associated Kinases | 1 | 2004 | 7 | 0.060 |
Why?
|
Ischemia | 1 | 2004 | 92 | 0.060 |
Why?
|
Gels | 1 | 2004 | 33 | 0.060 |
Why?
|
Cholesterol, HDL | 1 | 2004 | 164 | 0.060 |
Why?
|
Anoikis | 1 | 2003 | 2 | 0.060 |
Why?
|
Tropomyosin | 1 | 2003 | 3 | 0.060 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2004 | 72 | 0.060 |
Why?
|
Myocardium | 1 | 2004 | 170 | 0.060 |
Why?
|
Retrospective Studies | 6 | 2009 | 3107 | 0.060 |
Why?
|
Coronary Vessels | 1 | 2004 | 147 | 0.060 |
Why?
|
Embolism | 1 | 2003 | 6 | 0.060 |
Why?
|
Drosophila Proteins | 1 | 2003 | 43 | 0.060 |
Why?
|
RNA, Ribosomal, 28S | 1 | 2002 | 1 | 0.060 |
Why?
|
Mesenteric Vascular Occlusion | 1 | 2003 | 12 | 0.060 |
Why?
|
Versicans | 1 | 2002 | 4 | 0.060 |
Why?
|
Venae Cavae | 1 | 2002 | 3 | 0.060 |
Why?
|
Blotting, Northern | 1 | 2002 | 26 | 0.060 |
Why?
|
Lectins, C-Type | 1 | 2002 | 10 | 0.060 |
Why?
|
In Situ Hybridization | 1 | 2002 | 35 | 0.060 |
Why?
|
Angiotensin I | 1 | 2005 | 262 | 0.060 |
Why?
|
Carcinoma | 1 | 2003 | 87 | 0.060 |
Why?
|
Thrombosis | 1 | 2003 | 60 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2019 | 3099 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2005 | 420 | 0.050 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2002 | 47 | 0.050 |
Why?
|
Kidney Diseases | 1 | 2004 | 239 | 0.050 |
Why?
|
Adult | 6 | 2019 | 8391 | 0.050 |
Why?
|
Mass Spectrometry | 3 | 2007 | 99 | 0.050 |
Why?
|
Immunohistochemistry | 3 | 2009 | 519 | 0.050 |
Why?
|
Atherosclerosis | 1 | 2006 | 691 | 0.050 |
Why?
|
Kidney | 1 | 2004 | 485 | 0.050 |
Why?
|
Risk Assessment | 2 | 2019 | 1300 | 0.040 |
Why?
|
Catheter-Related Infections | 1 | 2019 | 10 | 0.040 |
Why?
|
Postthrombotic Syndrome | 1 | 2019 | 1 | 0.040 |
Why?
|
Stockings, Compression | 1 | 2019 | 2 | 0.040 |
Why?
|
Fibrinolysis | 1 | 2019 | 7 | 0.040 |
Why?
|
Catheterization, Peripheral | 1 | 2019 | 24 | 0.040 |
Why?
|
Thromboembolism | 1 | 2019 | 30 | 0.040 |
Why?
|
Forecasting | 1 | 2019 | 133 | 0.040 |
Why?
|
Fibrinolytic Agents | 1 | 2019 | 70 | 0.040 |
Why?
|
Hemorrhage | 1 | 2019 | 90 | 0.040 |
Why?
|
Brain | 1 | 2004 | 930 | 0.040 |
Why?
|
Breast Neoplasms | 1 | 2003 | 666 | 0.040 |
Why?
|
Patient Compliance | 1 | 2019 | 208 | 0.040 |
Why?
|
Postoperative Complications | 3 | 2006 | 670 | 0.030 |
Why?
|
Chromatography, Liquid | 2 | 2007 | 42 | 0.030 |
Why?
|
Amino Acid Sequence | 2 | 2007 | 280 | 0.030 |
Why?
|
Molecular Sequence Data | 2 | 2007 | 350 | 0.030 |
Why?
|
Incidence | 2 | 2009 | 1105 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2012 | 871 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2009 | 863 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2002 | 1007 | 0.030 |
Why?
|
Survival Rate | 2 | 2009 | 795 | 0.030 |
Why?
|
Quality of Life | 1 | 2019 | 815 | 0.030 |
Why?
|
Organizational Objectives | 1 | 2013 | 22 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2013 | 25 | 0.030 |
Why?
|
Ultrasonography, Doppler, Pulsed | 1 | 2012 | 5 | 0.030 |
Why?
|
Angiography, Digital Subtraction | 1 | 2012 | 18 | 0.030 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2012 | 17 | 0.030 |
Why?
|
Equipment Failure Analysis | 1 | 2012 | 42 | 0.030 |
Why?
|
Punctures | 1 | 2012 | 32 | 0.030 |
Why?
|
Needles | 1 | 2012 | 28 | 0.030 |
Why?
|
Prosthesis Failure | 1 | 2012 | 43 | 0.030 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 88 | 0.030 |
Why?
|
Inflammation | 2 | 2007 | 503 | 0.030 |
Why?
|
Young Adult | 1 | 2019 | 2398 | 0.030 |
Why?
|
Models, Animal | 1 | 2012 | 160 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2012 | 262 | 0.030 |
Why?
|
Actins | 1 | 2011 | 52 | 0.020 |
Why?
|
Adolescent | 1 | 2019 | 3248 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2011 | 74 | 0.020 |
Why?
|
Carotid Artery, Common | 1 | 2011 | 37 | 0.020 |
Why?
|
Pilot Projects | 1 | 2012 | 469 | 0.020 |
Why?
|
Femoral Artery | 1 | 2011 | 44 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2011 | 113 | 0.020 |
Why?
|
Vasoconstrictor Agents | 1 | 2011 | 62 | 0.020 |
Why?
|
Hematology | 1 | 2009 | 5 | 0.020 |
Why?
|
Colony-Forming Units Assay | 1 | 2009 | 17 | 0.020 |
Why?
|
Chromatography, Affinity | 1 | 2009 | 15 | 0.020 |
Why?
|
Ultrasonography, Doppler, Duplex | 1 | 2009 | 45 | 0.020 |
Why?
|
Cell Count | 1 | 2009 | 50 | 0.020 |
Why?
|
Glycoproteins | 1 | 2009 | 34 | 0.020 |
Why?
|
Probability | 1 | 2009 | 150 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2009 | 140 | 0.020 |
Why?
|
Angiography | 1 | 2009 | 75 | 0.020 |
Why?
|
Sex Distribution | 1 | 2009 | 185 | 0.020 |
Why?
|
Platelet Adhesiveness | 1 | 2008 | 13 | 0.020 |
Why?
|
Kinetics | 1 | 2009 | 205 | 0.020 |
Why?
|
Age Distribution | 1 | 2009 | 197 | 0.020 |
Why?
|
Antigens, CD | 1 | 2009 | 100 | 0.020 |
Why?
|
Peptides | 1 | 2009 | 118 | 0.020 |
Why?
|
Blood Pressure | 1 | 2012 | 803 | 0.020 |
Why?
|
Hypertrophy | 1 | 2007 | 26 | 0.020 |
Why?
|
Phenylephrine | 1 | 2007 | 27 | 0.020 |
Why?
|
Registries | 1 | 2009 | 278 | 0.020 |
Why?
|
Serotonin | 1 | 2007 | 35 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 248 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2009 | 706 | 0.020 |
Why?
|
Phlebography | 1 | 2007 | 26 | 0.020 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2007 | 91 | 0.020 |
Why?
|
Medical Records | 1 | 2007 | 68 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2006 | 73 | 0.020 |
Why?
|
Reconstructive Surgical Procedures | 1 | 2008 | 190 | 0.020 |
Why?
|
Pulmonary Embolism | 1 | 2007 | 46 | 0.020 |
Why?
|
Lipid Metabolism | 1 | 2007 | 100 | 0.020 |
Why?
|
Tunica Media | 1 | 2005 | 29 | 0.020 |
Why?
|
Creatinine | 1 | 2006 | 173 | 0.020 |
Why?
|
Atenolol | 1 | 2005 | 6 | 0.020 |
Why?
|
Hydralazine | 1 | 2005 | 8 | 0.020 |
Why?
|
Rats, Inbred SHR | 1 | 2005 | 42 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2006 | 286 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2005 | 59 | 0.020 |
Why?
|
Tetrazoles | 1 | 2005 | 71 | 0.020 |
Why?
|
Vasodilator Agents | 1 | 2005 | 54 | 0.020 |
Why?
|
Mesenteric Artery, Inferior | 1 | 2004 | 2 | 0.020 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 68 | 0.020 |
Why?
|
Mesenteric Artery, Superior | 1 | 2004 | 8 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2005 | 83 | 0.020 |
Why?
|
Imidazoles | 1 | 2005 | 104 | 0.020 |
Why?
|
Nitrogen | 1 | 2004 | 6 | 0.020 |
Why?
|
Peroxynitrous Acid | 1 | 2004 | 6 | 0.020 |
Why?
|
Lipid Peroxides | 1 | 2004 | 8 | 0.020 |
Why?
|
Taurine | 1 | 2004 | 6 | 0.020 |
Why?
|
Epitopes | 1 | 2004 | 21 | 0.020 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2004 | 26 | 0.020 |
Why?
|
Apolipoprotein A-I | 1 | 2004 | 68 | 0.020 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2005 | 142 | 0.020 |
Why?
|
Nitric Oxide | 1 | 2004 | 116 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2003 | 56 | 0.010 |
Why?
|
Oxygen | 1 | 2004 | 139 | 0.010 |
Why?
|
Genes, Tumor Suppressor | 1 | 2003 | 36 | 0.010 |
Why?
|
Survival Analysis | 1 | 2004 | 440 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2003 | 158 | 0.010 |
Why?
|
Angiotensin II | 1 | 2005 | 279 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2003 | 57 | 0.010 |
Why?
|
Peritonitis | 1 | 2003 | 10 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2003 | 72 | 0.010 |
Why?
|
Nephrectomy | 1 | 2004 | 114 | 0.010 |
Why?
|
Chronic Disease | 1 | 2004 | 369 | 0.010 |
Why?
|
Mesenteric Arteries | 1 | 2003 | 18 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2004 | 636 | 0.010 |
Why?
|
Comorbidity | 1 | 2004 | 539 | 0.010 |
Why?
|
Morbidity | 1 | 2003 | 91 | 0.010 |
Why?
|
North Carolina | 1 | 2007 | 1422 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2003 | 531 | 0.010 |
Why?
|
Intraoperative Complications | 1 | 2002 | 49 | 0.010 |
Why?
|
Random Allocation | 1 | 2002 | 212 | 0.010 |
Why?
|
Logistic Models | 1 | 2003 | 725 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2003 | 481 | 0.010 |
Why?
|
Length of Stay | 1 | 2002 | 291 | 0.010 |
Why?
|
Age Factors | 1 | 2002 | 1105 | 0.010 |
Why?
|
Risk Factors | 1 | 2004 | 3509 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2002 | 3712 | 0.010 |
Why?
|